Can phthalates, PFAS, and parabens interfere with male steroidogenesis and androgen signaling?

Environmental exposure to phthalates, per- and polyfluoroalkyl substances (PFAS), and parabens represents a critical area of clinical concern due to their capacity to act as endocrine-disrupting chemicals, particularly in aging populations.

Mechanistic pathways of endocrine disruption

• Steroidogenic enzyme inhibition: Phthalate metabolites like mono-(2-ethylhexyl) phthalate (MEHP) and PFAS congeners (such as PFOA and PFDoA) directly suppress the steroidogenic acute regulatory (StAR) protein in Leydig cells, disrupting rate-limiting mitochondrial cholesterol transport. MEHP also selectively downregulates CYP17A1 expression, blocking the conversion of progesterone to androgen precursors.
• Androgen receptor antagonism: All three compound classes function as competitive androgen receptor (AR) antagonists. MEHP exhibits AR inhibition with IC50 values spanning the nanomolar to micromolar range. Engineered PFAS act as low-micromolar antagonists, while long-chain parabens (such as hexyl- and heptylparaben) display high-potency AR antagonism with nanomolar IC50 values.

Impact on testosterone availability

• Age-related vulnerability: Population data from NHANES demonstrate that urinary metabolites of high-molecular-weight phthalates—specifically di(2-ethylhexyl) phthalate (DEHP) metabolites—are significantly associated with lower total, free, and bioavailable testosterone in aging men (aged 40 to 60 and older).
• Chemical-specific associations: Legacy long-chain PFAS, specifically PFOA and PFNA, are consistently correlated with lower serum testosterone. Conversely, individual paraben exposure is rarely associated with low testosterone in isolation, with its impact primarily observed within cumulative multi-pollutant mixture models.

Thyroid immune modulation

• Autoimmune pathways: While large-scale human epidemiological studies show mixed associations between these chemicals and hallmark thyroid autoantibodies (TPOAb and TgAb) in the general population, animal models provide strong mechanistic plausibility. In rodent models, oral exposure to dibutyl phthalate (DBP) significantly elevates TPOAb and TgAb titers and induces thyroiditis via oxidative stress, Th1/Th2/Th17 cytokine imbalances, and pro-inflammatory signaling.

Bottom line

• Phthalates and specific PFAS (PFOA and PFNA) are clinically and mechanistically linked to lower testosterone availability in aging men through the inhibition of Leydig cell steroidogenesis (StAR and CYP17A1) and direct androgen receptor antagonism. While their link to thyroid autoantibodies is highly variable in human cohorts, robust animal models confirm they can plausibly accelerate thyroid autoimmune pathology under susceptible conditions.